Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow
…
25,275€
-1,94%
Echtzeit-Aktienkurs Capricor Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Capricor Therapeutics Inc. Aktie
Capricor (CAPR) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEThursday, March 12, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Linda MarbánChief Financial Officer…
Capricor Therapeutics falls on Q4 earnings miss
Capricor Therapeutics falls on Q4 earnings miss…
Capricor Therapeutics (CAPR) im Pivotal-Point-Check: FDA-Durchbruch bei Herzmuskel-Therapie entfacht Kursrallye - Das ist der Fahrplan zur Zulassung!
FDA hebt Prüfstopp auf: Die US-Gesundheitsbehörde akzeptiert den Neuantrag für das Medikament Deramiocel und setzt ein finales Entscheidungsdatum auf den 22.…
Capricor Therapeutics stock surges on FDA BLA review resumption
Capricor Therapeutics stock surges on FDA BLA review resumption…
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
…
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
…
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy - Slideshow
…
CAPR Stock Skyrockets 282% in a Week: Heres What You Need to Know
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne…
Capricor Therapeutics stock tumbles after Martin Shkreli short call By Investing.com
Capricor Therapeutics stock tumbles after Martin Shkreli short call…
Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript
…
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway
…
Capricor Therapeutics, Inc. (CAPR) DMD Program Update Call (Transcript)
…
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
Capricor Therapeutics: Buying Opportunity Following FDAs Complete Response Letter
…
Capricor Therapeutics shares tumble as FDA rejects Duchenne muscular dystrophy drug application
Capricor Therapeutics (NASDAQ:CAPR) shares plummeted more than 26% after it reported the US Food and Drug Administration (FDA) has not…
US FDA declines to approve Capricors muscle disorder therapy
Capricor Therapeutics said on Friday the U.S. Food and Drug Administration has declined to approve its cell therapy deramiocel for…
Capricor Therapeutics (CAPR): H.C. Wainwright bestätigt Kaufempfehlung mit 805 % Kurspotenzial - Panikreaktion könnte Einstiegsgelegenheit bieten!
Capricor Therapeutics (CAPR) ist ein aufstrebendes Biotechnologieunternehmen, das sich auf die Entwicklung transformativer Zell- und Exosomen-basierter Therapeutika zur Behandlung seltener…
Capricor Therapeutics stock plunges after key FDA officials placed on leave By Investing.com
Capricor Therapeutics stock plunges after key FDA officials placed on leave…
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility By Investing.com
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility…
Capricor Therapeutics (CAPR): Experten von Roth Capital sehen 192 % Kurspotenzial!
Capricor Therapeutics (CAPR) ist ein Biotechnologieunternehmen mit Fokus auf Zell- und Exosomen-basierte Therapien für seltene Krankheiten. Der Konzern hat am…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education (NASDAQ:CLEU), Capricor Therapeutics (NASDAQ:CAPR)
…
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education (NASDAQ:CLEU), Capricor Therapeutics (NASDAQ:CAPR)
…
Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript
…
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of 48.39% and 248.28%, respectively, for the quarter ended December 2024. Do the…
Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com
Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance…
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data
…
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
…
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of -9.38% and 11.95%, respectively, for the quarter ended June 2024. Do the…
CORRECTION: Capricor Therapeutics
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces…
Capricor Therapeutics files for $150M mixed shelf
…
Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform
…
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
…
Capricor Therapeutics Q1 2024 Earnings Preview
…
Ausblick: Capricor Therapeutics präsentiert Quartalsergebnisse
Capricor Therapeutics wird am 13.05.2024 die Geschäftsergebnisse zum jüngsten Jahresviertel vorstellen.Die Schätzungen von 3 Analysten gehen beim Ergebnis je Aktie…
Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript
…